Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Operations (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Cash from Operations for 13 consecutive years, with 679000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 92.09% to 679000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 13504000.0 through Dec 2025, up 11.52% year-over-year, with the annual reading at 13504000.0 for FY2025, 11.52% up from the prior year.
  • Cash from Operations for Q4 2025 was 679000.0 at Niagen Bioscience, down from 3692000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 8583000.0 in Q4 2024, with the low at 7895000.0 in Q2 2021.
  • Average Cash from Operations over 5 years is 326550.0, with a median of 345500.0 recorded in 2023.
  • The sharpest move saw Cash from Operations plummeted 22572.73% in 2021, then soared 2572.2% in 2025.
  • Over 5 years, Cash from Operations stood at 4944000.0 in 2021, then soared by 93.37% to 328000.0 in 2022, then surged by 297.87% to 649000.0 in 2023, then surged by 1222.5% to 8583000.0 in 2024, then plummeted by 92.09% to 679000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 679000.0, 3692000.0, and 1250000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.